Optimizing Clinical Trial Logistics For On-Time Delivery

By Miguel Silva

Why OTD Remains Elusive

If organizations have more data, better technology, and highly-specialized vendors, with real-time visibility, the IoT, digital twins, AI, blockchain, and much more, why do delays continue to affect timelines? What is holding companies back from faster execution?

The answer is far from trivial, but it certainly implies creating distance from a common misconception – the belief that logistics performance can be easily outsourced, just like logistics execution.

Execution segments can certainly be delegated, but performance management and accountability cannot. Sustainable OTD performance requires governance, accountability, escalation models, visibility, and resilience – all of which are sponsor-centric.

Beyond Outsourcing

Outsourcing has transformed clinical supply chains by providing access to global infrastructure, scale, technology, and expertise that would be difficult for most sponsors to develop internally.

Vendors naturally optimize against contractual obligations, operational efficiency, and financial sustainability. Sponsors, meanwhile, optimize for study continuity, patient safety, protocol adherence, and end-to-end timelines. Those objectives overlap considerably, but they are not identical – and this difference matters.

Established requirements on key metrics reporting are typically included within contract frameworks, but metrics visibility rarely solves performance problems by itself: extensive reporting, frequent operational meetings, and large volumes of performance data result in relatively few structural improvements. Research consistently points in this direction – visibility only creates value when organizations translate information into timely decisions supported by appropriate governance and cross-functional collaboration.¹

Data without action becomes operational noise.

Governance Before Technology

Technology frequently receives credit—or blame—for logistics performance. In practice, organizational design, structure, systems, and governance often have a much greater influence.

Clinical trial logistics is inherently cross-functional: Forecasting depends on clinical operations, import readiness involves regulatory, vendor qualification requires procurement and quality, manufacturing and packaging determine product availability, while vendors and service providers execute transportation and depot operations.

Each additional organizational boundary introduces another opportunity for communication delays, inconsistent priorities, and fragmented ownership. Organizations often respond by increasing meetings, requesting additional reports, and expanding communication channels. Ironically, these activities can consume considerable operational capacity without addressing the underlying causes of delay.

The objective should not be to communicate more. It should be to ensure that the right information is available to the right people at the right time.

Integrated visibility across internal systems and external partners reduces manual information requests and enables faster decision-making. However, technology alone cannot achieve this. Clear ownership, well-defined escalation paths, and objective-driven governance remain essential to translate capabilities into results.

Recent research points to the critical role of implementing technology within governance models, rather than in isolation; this was shown as critical during high-disruptive scenarios.^2,3 Therefore, performance management should not only focus on reviewing KPIs but mostly on enabling decisions early enough to influence outcomes.

Three Pillars For Sustainable On-Time Delivery

Organizations that consistently achieve strong logistics performance and display robust resilience tend to be very mature on these characteristics:

1. Establish End-to-End Governance

High-performing organizations measure success across the complete supply chain rather than individual segments. OTD is OTD from vendor to clinical site. But it is also from manufacturing to packaging, packaging to distribution, manufacturing to patient, and any other segment or milestone within this value chain.

Clinical operations, procurement, quality, manufacturing, planning, packaging, and logistics all contribute to delivery performance. Measuring departments independently often creates local optimization while compromising overall study performance.

Instead, sponsors should establish governance frameworks that define clear accountability across the entire logistics process. Cross-functional meetings should become decision forums rather than reporting sessions. Escalation responsibilities should be predetermined.

Operational complexity cannot be eliminated, but it can be managed through governance rather than visibility or communication alone. Performance measurement should also focus on meaningful indicators and aligned with company objectives. These indicators should be built with the operational context in mind.

On-time delivery remains one of the industry's most important KPIs, and it is a great example of this. OTD should never be evaluated in isolation. Delivery targets themselves may change over time (think reschedules, site availability, delayed readiness, etc.). Looking at OTD targets that are continuously moved may create artificial improvements in performance.

For this, lead times to delivery provide essential context. Together, these metrics reveal whether organizations are genuinely improving responsiveness or simply extending delivery commitments.

2. Resilience And Performance Through Vendor Diversification

Vendor management remains one of the most underutilized strategic levers in clinical trial logistics.

Many sponsors have consolidated activities among a limited number of global logistics providers to simplify governance and achieve economies of scale. While operationally attractive, excessive concentration also increases dependence.

The clinical trial logistics market has relatively few providers capable of supporting global GDP-compliant operations at scale. If a core vendor experiences significant disruption, viable alternatives often exist only within contingency documents rather than operational reality. While it is common practice to identify secondary or backup suppliers, often these are not in a an operationally ready state, meaning already executing operations at scale.

Supply chain resilience research highlights supplier readiness as critical to recovering from unexpected events.⁴ This is hardly achievable with suppliers not already performing live operations at scale.

Vendor diversification is also deeply connected with performance management. With appropriate diversification, strategic allocation of business can be deployed, with each vendor striving to demonstrate superior OTD, lead times, compliance, and reactivity within a win-win framework where competition becomes a strong performance driver.

3. Use Technology To Accelerate Execution — Not As A Strategy

Technology continues to transform clinical trial logistics. Visibility platforms, control towers, integrated planning tools, and artificial intelligence all offer significant opportunities to improve operational performance.

However, technology should remain an enabler rather than the strategy itself.

Organizations frequently invest in dashboards that provide unprecedented transparency, yet transparency alone does not improve performance. The focus is not to know more. It is to decide better and faster. Technology should therefore be evaluated according to the operational decisions it enables rather than the sophistication of its interface.

Artificial intelligence represents perhaps the greatest opportunity currently facing clinical trial logistics. Numerous repetitive activities — including shipment monitoring, documentation reviews, predictive alerts, and routine communications — can be partially automated, allowing experienced professionals to focus on higher-value work such as network design, vendor strategy, and risk management.

At the same time, AI introduces new challenges.

Regulated environments require explainable, auditable, and compliant decision-making. AI systems therefore require robust governance, high-quality data, and appropriate human oversight.

Cybersecurity also deserves increasing attention. As supply chains become more interconnected and AI capabilities expand, cyber threats become increasingly sophisticated. Sponsors should balance automation with appropriate governance and security controls.

While technology amplifies good governance, it is not a substitute for it.⁵

Resilience As A Primary Objective

The greatest differentiator between average and high-performing supply chains is rarely found in transportation networks or digital platforms. It lies in supply chain preparedness and resilience.

The last several years have demonstrated that geopolitical instability, regulatory change, cyberattacks, and constrained logistics capacity are no longer exceptional events. Clinical trials operate within highly regulated environments where patient safety and product integrity leave little room for operational failure or delays.

Supply chain performance should therefore be measured not only by how efficiently operations perform under normal conditions but also by how effectively they continue operating during disruption.

Maintaining regional logistics partners, core internal capabilities, and regularly exercised contingency plans requires investment. However, this investment should be evaluated against the consequences of delayed patient dosing, interrupted studies, and extended end-to-end clinical trial timelines. While eliminating risk altogether may be unrealistic, taking steps to ensure no single disruption can compromise an entire supply chain is something sponsors should aspire to.

Conclusion

Clinical trial logistics has become increasingly sophisticated. Digital platforms provide unprecedented visibility, AI is beginning to automate routine operational tasks, and specialized logistics providers continue expanding their capabilities.

These developments are important. None of them, however, fundamentally changes what drives reliable on-time delivery. Consistent performance depends on strong governance, pragmatic performance management, end-to-end accountability, and resilient supply chain strategies.

Sponsors that rely exclusively on technology or outsourcing will continue to achieve incremental improvements while remaining vulnerable to structural weaknesses. Those that combine digital capabilities with diversified vendor strategies, operational readiness and clear accountability will be better positioned to sustain performance under both routine and disruptive conditions.

Ultimately, optimizing clinical trial logistics is not about building the fastest supply chain. It is about building one that continues delivering when circumstances inevitably change. That resilience may become the industry's most valuable competitive advantage.

References

1. Agrawal, T. K., Kalaiarasan, R., Olhager, J., & Wiktorsson, M. (2024). Supply chain visibility: A Delphi study on managerial perspectives and priorities. International Journal of Production Research, 62(8), 2927–2942. https://doi.org/10.1080/00207543.2022.2098873
2. Li, Y., Li, D., Liu, Y. et al. Digitalization for supply chain resilience and robustness: The roles of collaboration and formal contracts. Front. Eng. Manag. 10, 5–19 (2023). https://doi.org/10.1007/s42524-022-0229-x
3. Manisha Tiwari, David J. Bryde, Foteini Stavropoulou, Rameshwar Dubey, Sushma Kumari, Cyril Foropon. Modelling supply chain Visibility, digital Technologies, environmental dynamism and healthcare supply chain Resilience: An organisation information processing theory perspective, https://doi.org/10.1016/j.tre.2024.103613
4. Wei′an, L., & Yin, M. (2023). Research on supply chain emergency governance: A literature review based on bibliometric analysis. Journal of Contingencies and Crisis Management, 31, 683–705. https://doi.org/10.1111/1468-5973.12471
5. Adane Kassa, Daniel Kitaw, Ulrich Stache, Birhanu Beshah, Getachew Degefu, Artificial intelligence techniques for enhancing supply chain resilience: A systematic literature review, holistic framework, and future research, https://doi.org/10.1016/j.cie.2023.109714.

About The Author

Miguel Silva is a Pharma Supply Chain Manager and Consultant specializing in supply chain performance, scalability, resilience, and change management within global pharmaceutical environments. He has expertise in both third-party and in-house operations, designing and enabling clinical trial supply operations across complex, highly regulated settings. His areas of focus include end-to-end supply chain strategy and management, governance models, supply chain resilience, operational flexibility, and preparedness for disruptive scenarios. Through his strategic and operational expertise, Miguel helps organizations strengthen supply chain capabilities and navigate evolving challenges across the pharmaceutical landscape.